SCHEMBL71884

SCHEMBL71884

CCOC(=O)c1ccc(Cl)nc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.68
L3MBTL1 Q9Y468 4/20 0.67
RAB9A P51151 3/20 0.67
POLB P06746 2/20 0.67
MAPT P10636 2/20 0.67
PKM P14618 1/20 0.67
KDM4E B2RXH2 1/20 0.61
GAA P10253 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.58
LMNA P02545 1/20 0.57
NAPRT Q6XQN6 1/20 0.55
CHRNB2 P17787 1/20 0.54
CHRNA7 P36544 1/20 0.54
CHRNA4 P43681 1/20 0.54
TDP1 Q9NUW8 1/20 0.53
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
ESR1 P03372 1/20 0.53
CA7 P43166 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29723823 1.00 DGAT1 (0.68) DGAT1L3MBTL1RAB9APOLBMAPT
SCHEMBL1043248 0.87 L3MBTL1 (0.54) DGAT1L3MBTL1RAB9APOLBMAPT
SCHEMBL5241417 0.87 L3MBTL1 (0.63) DGAT1L3MBTL1RAB9APOLBMAPT
SCHEMBL6831884 0.84 L3MBTL1 (0.60) DGAT1L3MBTL1RAB9APOLBMAPT
SCHEMBL14560618 0.84 L3MBTL1 (0.63) DGAT1L3MBTL1RAB9APOLBMAPT
SCHEMBL9302968 0.84 POLB (0.60) DGAT1L3MBTL1RAB9APOLBMAPT
SCHEMBL9302975 0.84 POLB (0.60) DGAT1L3MBTL1RAB9APOLBMAPT
SCHEMBL13720405 0.82 TSHR (0.57) DGAT1L3MBTL1RAB9APOLBMAPT
SCHEMBL29800427 0.82 CA12 (0.56) L3MBTL1RAB9APOLBMAPTPKM
SCHEMBL659139 0.82 CA12 (0.56) L3MBTL1RAB9APOLBMAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 940 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109081835-B Preparation method of tazarotene without using cuprous iodide 重庆华邦胜凯制药有限公司 2022-04-12 CN claimed
CN-109081835-A A kind of preparation method of the tazarotene without using cuprous iodide 重庆华邦胜凯制药有限公司 2018-12-25 CN claimed
EP-2032536-B1 SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2015-05-06 EP claimed
EP-1700855-B1 A process for the preparation of tazarotene FIDIA FARMACEUTICI (IT) 2015-05-06 EP claimed
CN-101495456-B Substituted pyridyl amide compounds as modulators of the histamine H3 receptor JANSSEN PHARMACEUTICA NV 2014-03-19 CN claimed
US-7777031-B2 Substituted pyridyl amide compounds as modulators of the histamine H3 receptor JANSSEN PHARMACEUTICA NV (BE) 2010-08-17 US claimed
WO-2009116075-A2 PROCESS FOR PREPARATION OF TAZAROTENE INDOCO REMEDIES LIMITED (IN) 2009-09-24 WO claimed
CN-101495456-A Substituted pyridyl amide compounds as modulators of the histamine H3 receptor JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 CN claimed
EP-2032536-A2 SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-11 EP claimed
WO-2007143422-A2 SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-13 WO claimed
US-20070281923-A1 SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-06 US claimed
US-20060205950-A1 Process for the preparation of Tazarotene SOLMAG S.P.A. (IT) 2006-09-14 US claimed
EP-1700855-A1 A process for the preparation of tazarotene SOLMAG S.p.A. (IT) 2006-09-13 EP claimed
US-20060106233-A1 Process for the preparation of disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups GLENMARK PHARMACEUTICALS LIMITED (IN) 2006-05-18 US claimed
WO-2005123713-A1 PROCESS FOR THE PREPARATION OF DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS GLENMARK PHARMACEUTICALS LIMITED (US) 2005-12-29 WO claimed
US-12600696-B2 Aromatic compounds Xeniopro GmbH (DE) 2026-04-14 US disclosed
EP-4720060-A1 PRMT5 INHIBITORS Ryvu Therapeutics S.A. (PL) 2026-04-08 EP disclosed
EP-0284261-A1 Acetylenes disubstituted with a heteroaromatic group and a tetralin group having retinoid like activity ALLERGAN, INC (US) 1988-09-28 EP disclosed
EP-0284288-A1 Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity ALLERGAN, INC (US) 1988-09-28 EP disclosed
EP-0272921-A1 Ethynylheteroaromatic acids having retinoic acid-like activity ALLERGAN, INC (US) 1988-06-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205950-A1 Process for the preparation of Tazarotene DHPS, COASY, STS DGAT1 657/4885L3MBTL1 3985/4885RAB9A 2608/4885
US-20060106233-A1 Process for the preparation of disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups CBR3, NR1H2, NR3C2 DGAT1 3343/4885L3MBTL1 4278/4885RAB9A 3599/4885
US-20070281923-A1 SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR HRH3, HRH4, HRH2 DGAT1 4290/4885L3MBTL1 2849/4885RAB9A 1722/4885
US-12600696-B2 Aromatic compounds CCR1, CCRL2, AHR DGAT1 3876/4885L3MBTL1 116/4885RAB9A 3981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.